NextBioMedical Co

NextBioMedical Co Pre-Tax Margin

The Pre-Tax Profit Margin of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is -1.89 %. In the previous year, Pre-Tax Profit Margin was 29.97 % — a change of -106.30% (lower).

Pre-Tax Margin

-1.89 %

YoY

-106.30%

Last updated:

Pre-Tax Profit Margin of NextBioMedical Co is 2025 -1.89 % . Pre-Tax Profit Margin of NextBioMedical Co was 2024 29.97 % . It decreases by -106.30% lower compared to the previous year.

The NextBioMedical Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2021
-734.13 KRW
Jan 1, 2022
-205.07 KRW
Jan 1, 2023
-154.06 KRW
Jan 1, 2024
29.97 KRW
Jan 1, 2025
-1.89 KRW
The NextBioMedical Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
-1.89 %-106.30%
29.97 %-119.45%
-154.06 %-24.88%
-205.07 %-72.07%
-734.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Pre-Tax Profit Margin of NextBioMedical Co is -1.89 % in 2025.

Pre-Tax Profit Margin of NextBioMedical Co changed from 29.97 % to -1.89 %, representing a -106.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NextBioMedical Co

All Key Metrics — NextBioMedical Co